Lung cancer screening with a low-dose chest CT scan can result in more benefi t than harm when performed in settings committed to developing and maintaining high-quality programs.
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We believe that, when performed in an appropriate patient population in settings committed to quality, lung cancer screening with low-dose CT (LDCT) scanning will result in more benefi t than harm. Th e benefi ts and harms of lung cancer screening depend on a complex interplay of multiple factors. Lung cancer screening is not solely an imaging test; it is a process that should take place within an organized program. In the text that follows we outline the components of lung cancer screening programs that can infl uence the balance of benefi t and harms. We briefl y review the evidence base 
Materials and Methods
Committees with expertise in lung cancer screening were assembled by the Thoracic Oncology Network of the American College of Chest Physicians (CHEST) and the Th oracic Oncology Assembly of the American Th oracic Society (ATS). Participants included pulmonologists, thoracic surgeons, a chest radiologist, and health services policy experts with expertise in lung cancer CT scan screening as identifi ed by their publications and involvement in professional societies. Th e committees reviewed evidence-based guidelines related to lung cancer screening, including a combined review from CHEST, ATS, and American Society of Clinical Oncology, 1 a separate review from CHEST, 2 and the statement from the US Preventive Services Task Force (USPSTF). 3 Particular focus was given to the areas of these documents discussing implementation challenges. Th is review was supplemented by the experience of the committee members to develop a list of components of a lung cancer screening program that are capable of infl uencing the balance of benefi t to harm.
Th e evidence related to each component was summarized, and Policy Statements were developed based on the evidence. Consensus about the component descriptions and Policy Statements was achieved through incorporation of the iterative written and verbal feedback of the committees. Two quality metrics were developed based on our expert committee's consensus that the metrics are valid, feasible, and relevant. 
Results

Component 1: Who Is Off ered Lung Cancer Screening
The principal question is how do lung cancer screening programs identify a group at high enough risk of developing lung cancer to benefi t more than they are harmed. Th e balance with this choice is that more lives can be saved by screening at lower thresholds of risk, but the relative harms of screening increase as the threshold is lowered. It is diffi cult to determine the ideal balance of benefi t and harm, as the value of the benefi t and harms is not equal and varies with patient preferences.
Th e only group in which lung cancer screening has direct evidence of a proven benefit is the National Lung Screening Trial (NLST) cohort. 4 Based on the results of computer models of screening performed by the Cancer Intervention and Surveillance Modeling Network for the Agency for Healthcare Research and Quality, 5 the USPSTF extended the age limit for screening from 74 to 80 years in its recommendations. 3 Even within the NLST cohort, there is a wide range of risk for developing lung cancer and, thus, a wide range of the benefit to harm balance that can be expected 6 ( Table 1 ) .
Multiple models exist to help estimate the risk of developing lung cancer [7] [8] [9] [10] [11] ( Table 2 ) . One model, Prostate, Lung, Colorectal, Ovarian Screening Trial (PLCO 2012), was validated in comparison with the NLST criteria, showing marginally improved sensitivity with similar specifi city for identifying patients with lung cancer. 9 At this time, it is not clear that obtaining an equal risk through diff erent risk factors equates to equal benefi t from lung cancer screening.
Over the next several years, ongoing randomized controlled trials of diff erent study design could inform us about the potential balance of benefi t and harm in populations with lower and higher risk than those included in the NLST. Th e principal question is whether the benefi t seen in the NLST would be modifi ed by screening for longer periods or at diff erent intervals than were used in the NLST. Th e tradeoff with this choice is that the reduction in harm will lead to a reduction in the number of lung cancer deaths avoided.
USPSTF
Because of the expense and impracticality of performing a controlled trial lasting throughout the period of high risk (20-25 years) , this question may never have direct evidence to inform its answer. The NLST showed an equal number of stage I lung cancers during each incidence screening round and a slight narrowing of the cumulative incidence gap during the observation period. 4 This suggests that additional years of screening could have added to the benefit. Other controlled trials of variable design have found similar portions of early-and late-stage cancers regardless of design. 12 The modeling performed for the [
USPSTF found maximal benefit, and the greatest efficiency, in the models that incorporated annual screening (to age 80 years) 5 ( Fig 1 ) .
USPSTF Recommendation 3 :
1. Annual screening until age 80 years. 2. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.
For Qualifi cation as a Lung Cancer Screening Facility:
1. Th e lung cancer screening program must confi rm that there is a policy about the frequency and duration of screening that is in keeping with the USPSTF recommendation.
Future Research: Tools should be developed to assess life expectancy based on age and comorbidities, to provide a quantifiable reason to exclude patients who are unlikely to benefit from lung cancer screening because they are at too high a risk of dying of another cause.
Component 3: How the CT Scan Is Performed
This component refers to the ability of a program to ensure performance of the CT scan with reduceddose techniques similar to those used in the NLST.
The American College of Radiology (ACR) and Society of Thoracic Radiology (STR) have developed technical specifications for the performance of a LDCT 13 ( e- Table 1 ).
Policy Statements:
1. A low-dose lung cancer screening CT scan should be performed based on the ACR-STR technical specifi cations. 2. A lung cancer screening program should collect data to ensure the mean radiation dose is in compliance with ACR-STR recommendations.
1. Th e lung cancer screening program must confi rm that there is a policy about the technical specifi cations for performing low-dose CT scan screening that is in keeping with the ACR-STR technical specifi cations and credentialing criteria.
Future Research: Evaluation of new CT scanner algorithms and ultra-low-dose imaging techniques to assess the impact of reducing harm from radiation exposure on nodule detection rates.
Component 4: Lung Nodule Identifi cation
Th e principal question is what nodule size threshold should be used to label the screen as positive. Th e balance with this choice is that a lower threshold will lead to fewer lung cancers being missed but will increase the false-positive rate.
Th e NLST and other screening trials have shown that the majority of the nodules identifi ed are solid and Յ 5 mm in diameter. Th ese very small nodules have a very low probability of being malignant. 14, 15 Based on current nodule management guidelines, most of these nodules can be safely monitored at the time of the annual screening CT scan. In the NLST, raising the size threshold from 4 to 7 mm would have decreased the number of nodules identifi ed by . 50% and would have resulted in approximately 7% of the cancer diagnoses being delayed 14, 15 ( Table 3 ) .
In well-supported controlled trials of CT scan screen ing there are subjects who are not adherent with their annual screen or are lost to follow-up ( Table 4 ) . Th e Continuous Observation of Smoking Subjects (COSMOS) trial reported 21% loss to follow-up over 5 years. 16 Th is number is likely to be larger in clinical practice. As the size threshold for nodule identifi cation is increased, the issue of nonadherence becomes a greater concern. Having a nodule may improve adherence with follow-up, although this has not been directly studied.
Patient distress has been reported around the identifi cation of a lung nodule. 18 Rates of smoking abstinence may be related to the identifi cation of a nodule. 19 Th ere is no direct evidence linking the nodule size threshold that is used to label the screen as positive to oncologic (eg, stage of cancer at diagnosis) or patient-centered outcomes. Future Research: Evaluation of oncologic and patientcentered outcomes based on the lung nodule size threshold used to label the screening test positive should occur.
Component 5: Structured Reporting
Screening programs should consider the format that they will use to report the results of the LDCT scan screen. A structured report must communicate the pertinent fi ndings to the ordering provider, defi ne what constitutes a positive fi nding on the LDCT, recommend nodule management strategies based on the algorithm accepted by the program, and be used to populate quality-control and evidence-development registries.
Th e ACR has developed a structured reporting system called LungRADS, based on the breast cancer screening structured reporting system BiRADS, designed to be a communication tool, to defi ne what constitutes a positive fi nding on the LDCT, and to be a lung nodule management strategy for low-risk nodules 20 ( e- Table 2 ) . Th e lung nodule management strategy is not iden tical to other available evidence-based guideline recommendations. 
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1. The lung cancer screening program is using LungRADS as their structured reporting system or uses a structured reporting system with similar elements (communication tool, identification of positive findings, lung nodule management recommendations). 2. Th e selected structured reporting system is being used for Ն 90% of the CT scan screen reports.
Future Research: Th e impact of structured reporting systems on oncologic and patient-centered outcomes, compliance with follow-up, and radiologist work-fl ow should be studied.
Component 6: Lung Nodule Management Algorithms
Lung nodules should be managed based on the probability that they are malignant. Management algorithms, based on risk of malignancy, are available for solid subcentimeter nodules, solid larger nodules (1-3 cm), and subsolid nodules. [20] [21] [22] [23] Th e appropriate management of screen-detected lung nodules will minimize additional imaging, minimize the number of invasive procedures performed for benign nodules, and facilitate the timely treatment of malignant nodules.
Solid subcentimeter nodules have a very low probability of being malignant 14 and are diffi cult to characterize by additional imaging or nonsurgical biopsies. Th us, surveillance imaging is the most appropriate management strategy. Th e interval of surveillance is based on the size of the nodule. Th ere are guidelines available about how frequently surveillance should occur [20] [21] [22] ( Table 5 ) . Evidence to support one of the guideline strategies over the other is not available.
Solid nodules . 1 cm have a higher probability of malignancy. Additional imaging and nonsurgical biopsies are more helpful for characterizing these nodules as benign or malignant. Management of nodules in this category begins with a review of prior imaging and is followed by an estimation of risk based on clinical and imaging variables. Very-low-risk nodules can enter a surveillance strategy, low-to moderate-risk nodules can be further characterized with PET imaging and/or a nonsurgical biopsy, and high-risk nodules may proceed directly to resection. In addition to the risk of malignancy, the choice of testing includes patient factors such as their comorbidities, general health, and values 21 ( e -Fig 1 ) .
Subsolid nodules, including pure ground-glass nodules and part-solid nodules, have a higher baseline risk of malignancy than solid nodules of equal size but are generally more indolent in their behavior when malignant. The majority of overdiagnosed screen-detected lung cancers will present as subsolid nodules. 24 The higher probability of malignancy and less aggressive behavior inform the management algorithm for subsolid nodules [20] [21] [22] ( e -Fig 2 ) .
The few patient-centered outcomes that have been reported in lung cancer screening trials reflect on the impact of fi nding a nodule on the patient's quality of life. 25 There is a growing body of evidence suggesting many patients lack an understanding of the meaning of a nodule and overestimate the risk of malignancy. 26, 27 Policy Statements: A lung cancer screening program must: a. the number of surveillance and diagnostic imaging tests, b. nonsurgical and surgical biopsies that are performed for malignant and benign screen-detected nodules, c. the number of cancer diagnoses, and d. the number of procedure related adverse events (eg, hospitalization, death)
Future Research: Th e impact of nodule management algorithms and communication tools on oncologic and patient-centered outcomes should be studied. Th e clinical usefulness of validated lung nodule molecular biomarkers should be studied. Means to characterize T1a lung cancers, and tools to estimate life expectancy, should be studied to better understand and minimize overdiagnosis.
Component 7: Smoking Cessation
The mortality reduction that could be achieved by smoking cessation exceeds that from lung cancer screening. 28 The impact of lung cancer screening on smoking cessation rates is poorly defined. Limited evidence suggests LDCT scan screening itself does not influence smoking behavior; however, the reporting of positive results may be associated with increased smoking abstinence. 19 Th e cost-eff ectiveness of screening improves with increasing rates of smoking cessation. 29 e- Table 3 lists smoking cessation resources.
Policy Statements:
1. A lung cancer screening program must be integrated with a smoking cessation program. 2. A lung cancer screening program should collect data related to the smoking cessation interventions that are off ered to active smokers enrolled in the screening program.
1. Th e lung cancer screening program has integrated smoking cessation services for patients enrolled in their program. 2. Th e lung cancer screening program will report on the portion of active smokers who are off ered, and who participate in, a smoking cessation intervention.
Future Research:
Th e impact of participation in a screening program, the results of screening, and the elements of a screening program on smoking cessation rates should be studied.
Component 8: Patient and Provider Education
Providers must understand the components of screening well enough that they can identify patients in the appropriate risk group, know how to interpret and manage the screening results, and be capable of helping their patients make value-based decisions about being screened. Th e lung cancer screening program is the source of education for the provider and should supplement the patient's education. e- Table 4 lists patient educational material resources. Future Research: Th e impact of provider education methods on compliance with screening metrics and the impact of patient education methods on their understanding of the benefi ts and harms of lung cancer screening should be studied.
Component 9: Data Collection
To ensure that a lung cancer screening program is maintaining quality standards, data collection and periodic review must occur. Data collection can also serve to advance our understanding of the science of screening. Ideally, a core set of data elements would be collected by all programs, and a means would be available to share data across programs, such as through a centralized lung cancer screening registry. 
Multisociety, Multidisciplinary Governance
Th ere are recognized implications of the content of this policy statement. Th e components of lung cancer screening programs outlined above demonstrate the multidisciplinary nature of the expertise required to develop and maintain a high-quality screening program. In addition, we have stressed that most of the components of a successful screening program will be optimized over time by incorporating knowledge gained through research. Finally, a credentialing system based on the qualifying elements suggested in each of the above components would have a broader mandate than that currently available.
Policy Statements:
1. A multisociety, multidisciplinary governance structure should be developed and supported to advance quality standards based on evolving evidence, administer an expanded credentialing system, and suggest research priorities. 2. At a minimum, the multisociety governance should oversee the evolution of structured reporting; nodule management algorithms; the structure, maintenance, and integrity of a lung cancer screening registry; the research conducted on the registry; and research that would help to defi ne the criteria for screening eligibility.
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